Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

KRAS G12C inhibitor JMKX001899

An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C, with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor JMKX001899 targets and irreversibly binds to the KRAS G12C mutant, and locks it in an inactive state. This inhibits the activity of the KRAS G12C mutant, thereby preventing KRAS G12C mutant-mediated signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis. JMKX001899 is able to penetrate through the blood-brain barrier (BBB).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:JMKX 001899
JMKX-001899
JMKX001899
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search